Comments
Drug firms SeQuent Scientific and Shasun Pharmaceuticals today said they have signed a letter of intent to form a joint venture company (JVC) to manufacture, develop and sell veterinary products.
The products will include both active pharmaceutical ingredients (APIs) and formulations will be sold globally, both companies said in a joint statement.
As per the letter of intent (LoI), SeQuent will own 73 per cent of the joint venture company (JVC) while Shasun will own the remaining 27 per cent ownership, it added.
“In the JVC, contributions will be made by both companies by way of transfer of identified assets, contracts and licences,” the statement said.
Commenting on the development, SeQuent Managing Director Gautam Kumar Das said: “The combination with Shasun will deliver synergies and technical arbitrage enabling the JVC to emerge as a leading global provider of animal health solutions.”
Shasun is an integrated, leading global supplier of development and manufacturing services for intermediates, API (Active Pharmaceutical Ingredients) and Formulations to the Pharmaceutical Industry.
Sequent is amongst India’s largest Custom Research and Manufacturing Services (CRAMS) providers.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.